SCHEMBL2430718

SCHEMBL2430718

Ic1ccc2nc(-c3ccc(-c4cc[nH]n4)cc3)cn2c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 6/20 0.59
NPC1 O15118 5/20 0.47
RAB9A P51151 5/20 0.47
ALDH1A1 P00352 4/20 0.47
PAX8 Q06710 2/20 0.47
KDM4E B2RXH2 2/20 0.47
KMT2A Q03164 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
MEN1 O00255 1/20 0.47
MITF O75030 1/20 0.47
KDM5A P29375 1/20 0.47
KDM5C P41229 1/20 0.47
ALDH1A3 P47895 8/20 0.46
ALDH1A2 O94788 1/20 0.46
MAP2K1 Q02750 1/20 0.43
SLC2A1 P11166 1/20 0.42
TP53 P04637 1/20 0.41
PKM P14618 1/20 0.41
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15177306 0.84 APP (0.73) APPNPC1RAB9AALDH1A1PAX8
SCHEMBL2430633 0.82 APP (0.59) APPNPC1RAB9AALDH1A1PAX8
SCHEMBL2427073 0.81 RAB9A (0.63) NPC1RAB9AALDH1A1KDM4EKMT2A
SCHEMBL24320031 0.80 NPC1 (0.74) APPNPC1RAB9AALDH1A1PAX8
SCHEMBL1726415 0.78 APP (0.66) APPNPC1RAB9AALDH1A1PAX8
SCHEMBL1985593 0.78 APP (0.66) APPNPC1RAB9AALDH1A1PAX8
SCHEMBL217156 0.78 RAB9A (0.75) APPNPC1RAB9AALDH1A1PAX8
SCHEMBL26603206 0.78 APP (0.69) APPNPC1RAB9AALDH1A1PAX8
SCHEMBL2904371 0.78 APP (0.66) APPNPC1RAB9AALDH1A1PAX8
SCHEMBL2429114 0.78 APP (0.58) APPNPC1RAB9AALDH1A1PAX8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1956013-B1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION FUJIFILM RI PHARMA CO LTD (JP) 2016-04-13 EP claimed
EP-1956013-B1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION FUJIFILM RI PHARMA CO LTD (JP) 2016-04-13 EP disclosed
EP-1956013-B1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION FUJIFILM RI PHARMA CO LTD (JP) 2016-04-13 EP disclosed
US-8022075-B2 Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition FUJIFILM RI PHARMA CO., LTD. (JP) 2011-09-20 US disclosed
US-8022075-B2 Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition FUJIFILM RI PHARMA CO., LTD. (JP) 2011-09-20 US disclosed
WO-2010128595-A1 METHOD FOR PRODUCING RADIOACTIVE IODINE-LABELED IMIDAZOPYRIDINE DERIVATIVE 富士フイルムRIファーマ株式会社 (JP) 2010-11-11 WO disclosed
US-20090162283-A1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION FUJIFILM RI PHARMA CO., LTD. (JP) 2009-06-25 US disclosed
EP-1956013-A1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION Fujifilm RI Pharma Co., Ltd. (JP) 2008-08-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090162283-A1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION APP, TTR, BACE1 APP 1/4885NPC1 533/4885RAB9A 3111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.